Keryx Biopharmaceuticals Inc. said it has started shipping Auryxia (ferric citrate) tablets to wholesalers in the United States. Auryxia is approved for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis, and is the only absorbable-iron-based phosphate binder that is clinically proven to effectively control phosphate levels within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. The U.S. Food and Drug Administration approved the drug in September 2014.
“Dialysis patients and their healthcare providers will benefit from having an additional phosphate binder available,” commented Julia Lewis, MD, nephrologist and Professor of Medicine at Vanderbilt University Medical Center. “Auryxia's clinical profile is compelling and I believe will be of value for my patients.”
The company said it has created the “Keryx Patient Plus” program to assist with patient accessibility to Auryxia. Beginning at the company’s reimbursement hub, personalized service is provided throughdedicated regional case managers to provide the renal care team with comprehensive insurance and reimbursement support for their patients. Keryx Patient Plus offers benefit verification, co-pay assistance for eligible commercial patients, free-drug program for those who qualify, and a short-term prescription bridge program that may assist those already on Auryxia who are in danger of suffering a break in coverage.